By Sarina Isaacs
American depositary receipts of EDAP slipped after the maker of robotic energy-based therapies posted a worse-than-expected loss for the first quarter.
EDAP's ADRs were recently down 21%, to $1.71, and have lost about three-quarters of their value over the past year.
The Vaulx-en-Velin, France, company on Thursday reported a first-quarter loss of $7.5 million, or 20 cents a share, compared with a loss of $4.9 million, or 13 cents a share, a year earlier.
Analysts were looking for a loss of 18 cents a share, according to FactSet.
Revenue fell to $14.3 million from $16.1 million in the prior year and below analysts' expectation of $16 million.
EDAP also reiterated its prior full-year guidance, expecting revenue growth of 16% to 25% in its core High Intensity Focused Ultrasound business and a decline of 20% to 25% for revenue in its non-core businesses.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
May 15, 2025 13:57 ET (17:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。